Thierry Poynard

Summary

Country: France

Publications

  1. pmc Meta-analyses of FibroTest diagnostic value in chronic liver disease
    Thierry Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Universite Paris VI, CNRS ESA 8067 Paris, France
    BMC Gastroenterol 7:40. 2007
  2. ncbi A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C
    Yen Ngo
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, CNRS, Paris, France
    Clin Chem 52:1887-96. 2006
  3. ncbi Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy
    Robert P Myers
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
    AIDS 18:75-9. 2004
  4. ncbi Viral hepatitis C
    Thierry Poynard
    Service d Hepato gastro enterologie, Groupe Hospitalier Pitie Salpetriere, Universite, Paris, France
    Lancet 362:2095-100. 2003
  5. ncbi FibroMAX: towards a new universal biomarker of liver disease?
    Rachel Morra
    Groupe Hospitalier Pitie Salpetriere, 47 83 boulevard de l Hopital, 75651 Paris Cedex 13, France
    Expert Rev Mol Diagn 7:481-90. 2007
  6. ncbi Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin
    Thierry Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Universite Paris VI, Paris, France
    Hepatology 38:481-92. 2003
  7. ncbi Biomarkers of liver fibrosis
    Thierry Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Universite Paris VI, CNRS ESA 8067 Paris, France
    Adv Clin Chem 46:131-60. 2008
  8. ncbi Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C
    Thierry Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Universite Paris VI, Paris, France
    Clin Chem 50:1344-55. 2004
  9. ncbi Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B
    Robert P Myers
    Department of Hepatology and Gastroenterology, Groupe Hospitalier Pitie Salpetriere, Paris, France
    J Hepatol 39:222-30. 2003
  10. pmc An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load
    Yen Ngo
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Universite Paris VI, CNRS UMR 8149, Paris, France
    PLoS ONE 3:e2573. 2008

Detail Information

Publications94

  1. pmc Meta-analyses of FibroTest diagnostic value in chronic liver disease
    Thierry Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Universite Paris VI, CNRS ESA 8067 Paris, France
    BMC Gastroenterol 7:40. 2007
    ....
  2. ncbi A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C
    Yen Ngo
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, CNRS, Paris, France
    Clin Chem 52:1887-96. 2006
    ..We compared the 5-year prognostic value of the FibroTest with biopsy staging for predicting cirrhosis decompensation and survival in patients with chronic HCV infection...
  3. ncbi Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy
    Robert P Myers
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
    AIDS 18:75-9. 2004
    ..Pegylated interferon alpha (PEG-IFN-alpha) and ribavirin is the most effective available treatment for chronic hepatitis C virus (HCV) infection. Its role in HIV/HCV-co-infected patients who have failed IFN-based therapy is unclear...
  4. ncbi Viral hepatitis C
    Thierry Poynard
    Service d Hepato gastro enterologie, Groupe Hospitalier Pitie Salpetriere, Universite, Paris, France
    Lancet 362:2095-100. 2003
    ..These antiviral treatments reduce liver fibrosis progression and can reverse cirrhosis. Unfortunately, even in developed countries, death due to hepatitis C is increasing because of inadequate detection and treatment...
  5. ncbi FibroMAX: towards a new universal biomarker of liver disease?
    Rachel Morra
    Groupe Hospitalier Pitie Salpetriere, 47 83 boulevard de l Hopital, 75651 Paris Cedex 13, France
    Expert Rev Mol Diagn 7:481-90. 2007
    ..The possible causes of false-negative and false-positive results are also better identified. These tests, which are now available in 50 countries, can facilitate the screening and management of the most frequent liver diseases...
  6. ncbi Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin
    Thierry Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Universite Paris VI, Paris, France
    Hepatology 38:481-92. 2003
    ..In conclusion, these biochemical markers of fibrosis and activity could be used as surrogate markers for liver biopsy in patients with chronic hepatitis C, both for the initial evaluation and for follow-up...
  7. ncbi Biomarkers of liver fibrosis
    Thierry Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Universite Paris VI, CNRS ESA 8067 Paris, France
    Adv Clin Chem 46:131-60. 2008
    ..Neither biomarkers nor biopsy are sufficient alone to take definitive decision in a given patient and all the clinical and biological data must be taken into account...
  8. ncbi Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C
    Thierry Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Universite Paris VI, Paris, France
    Clin Chem 50:1344-55. 2004
    ....
  9. ncbi Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B
    Robert P Myers
    Department of Hepatology and Gastroenterology, Groupe Hospitalier Pitie Salpetriere, Paris, France
    J Hepatol 39:222-30. 2003
    ..Liver biopsy is the gold standard for assessing hepatitis B virus (HBV)-related histology. The aim was to determine the diagnostic utility of noninvasive serum markers in patients with chronic hepatitis B...
  10. pmc An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load
    Yen Ngo
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Universite Paris VI, CNRS UMR 8149, Paris, France
    PLoS ONE 3:e2573. 2008
    ..We compared the 4-year prognostic value of combining FT-AT and viral load for a better definition of the inactive carrier status...
  11. pmc Concordance in a world without a gold standard: a new non-invasive methodology for improving accuracy of fibrosis markers
    Thierry Poynard
    APHP Groupe Hospitalier Pitié Salpétrière, Universite Paris VI, CNRS UMR, Paris, France
    PLoS ONE 3:e3857. 2008
    ..The aim was to identify factors associated with LSM accuracy using FT as a non-invasive endpoint and vice versa...
  12. doi Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease
    Sylvie Naveau
    Assistance Publique Hopitaux de Paris AP HP, Hopital Antoine Beclere, Service d Hepato Gastroenterologie, Clamart, France
    Hepatology 49:97-105. 2009
    ..03), without independent prognostic values for FibrometerA (P = 0.41) and Hepascore (P = 0.28). In patients with alcoholic liver disease, FibrometerA and Hepascore did not improve the diagnostic and prognostic values of FibroTest...
  13. ncbi The diagnostic value of biomarkers (AshTest) for the prediction of alcoholic steato-hepatitis in patients with chronic alcoholic liver disease
    Dominique Thabut
    Department of Hepato Gastroenterology, Groupe Hospitalier Pitie Salpetriere, 47 83 boulevard de l Hopital, 75651 CNRS UMR 8149, Paris Cedex 13, France
    J Hepatol 44:1175-85. 2006
    ..The aim was to identify a panel of biomarkers (AshTest) for the diagnosis of alcoholic steato-hepatitis (ASH), in patients with chronic alcoholic liver disease...
  14. ncbi Biochemical markers of fibrosis in patients with chronic hepatitis C: a comparison with prothrombin time, platelet count, and age-platelet index
    Robert P Myers
    Department of Gastroenterology and Hepatology, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Dig Dis Sci 48:146-53. 2003
    ..In conclusion, an index of five biochemical markers accurately predicts significant hepatitis C-related fibrosis and is superior to traditional markers...
  15. ncbi Natural history and predictors of disease severity in chronic hepatitis C
    Julien Massard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, 47 Boulevard de l Hopital, 75651 Paris Cedex 13, France
    J Hepatol 44:S19-24. 2006
    ..The recent validation of non-invasive biomarkers should facilitate the study of fibrosis progression in large populations...
  16. ncbi Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposure
    Vincent Di Martino
    Service d Hepato Gastroenterologie, GH Pitié Salpétrière, Paris, France
    Hepatology 40:1426-33. 2004
    ..Pregnancies may have a beneficial impact on the long-term progression of liver fibrosis...
  17. ncbi Treatment of cirrhotic patients in the pegylated interferon era
    Thierry Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Dig Liver Dis 36:S344-8. 2004
    ..Non-invasive biochemical markers of liver fibrosis should facilitate the management...
  18. pmc Assessment of liver fibrosis: noninvasive means
    Thierry Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Universite Paris VI, CNRS ESA 8149 Paris, France
    Saudi J Gastroenterol 14:163-73. 2008
    ..There is no evidence based data justifying biopsy as a first line estimate of liver fibrosis. Health authorities in some countries have already approved validated biomarkers as the first line procedure for the staging of liver fibrosis...
  19. pmc The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis
    Thierry Poynard
    Department of Hepato Gastroenterology, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Comp Hepatol 4:10. 2005
    ..Steatosis was blindly assessed by using a previously validated scoring system...
  20. ncbi Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C
    Thierry Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Universite Paris VI, Paris, France
    Hepatology 38:75-85. 2003
    ..In conclusion, sustained disappearance of the virus is associated with reduction of steatosis in genotype 3 as well as a correction of baseline low serum cholesterol...
  21. pmc Real time identification of drug-induced liver injury (DILI) through daily screening of ALT results: a prospective pilot cohort study
    Helmi M'Kada
    Service de Biochimie Métabolique, Groupe Hospitalier Pitie Salpetriere, Assistance Publique Hopitaux de Paris, Paris, France
    PLoS ONE 7:e42418. 2012
    ..Identification of drug-induced liver disease (DILI) is difficult, even among hospitalized patients. The aim of this pilot study was to assess the impact of a specific strategy for DILI screening...
  22. pmc Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C
    Thierry Poynard
    Groupe Hospitalier Pitie Salpetriere, 47 83 boulevard de l Hopital, 75651 Paris Cedex 13, France
    Comp Hepatol 3:8. 2004
    ..In clinical practice, liver biopsy should be recommended only as a second line test, i.e., in case of high risk of error of biochemical tests...
  23. ncbi Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection
    Thierry Poynard
    Department of Hepatology and Gastroenterology, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Am J Gastroenterol 100:1970-80. 2005
    ..The aim was to use these markers in a prospective study of patients treated with lamivudine in order to assess the impact of treatment, as well as the factors associated with fibrosis progression...
  24. ncbi Fat, diabetes, and liver injury in chronic hepatitis C
    Vlad Ratziu
    Service d Hepatogastroenterologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Curr Gastroenterol Rep 6:22-9. 2004
    ..Exciting new data are expanding our understanding of the mechanisms of steatogenesis in HCV infection and providing potential links between insulin resistance or hyperglycemic states and liver fibrogenesis...
  25. pmc Invasive pulmonary aspergillosis in patients with decompensated cirrhosis: case series
    Hélène Prodanovic
    Assistance Publique Hopitaux de Paris, Service de Pneumologie et Reanimation, Groupe Hospitalier Pitie Salpetriere, Paris, France
    BMC Gastroenterol 7:2. 2007
    ..Liver failure has been suspected to be a risk factor for aspergillosis...
  26. doi Improved inflammatory activity with peginterferon alfa-2b maintenance therapy in non-cirrhotic prior non-responders: a randomized study
    Thierry Poynard
    Service d Hepato Gastroenterologie, APHP UPMC Paris Liver Center, Paris, France
    J Hepatol 58:452-9. 2013
    ..EPIC(3) included a prospective trial assessing long-term peginterferon alfa-2b (PegIFNα-2b) maintenance therapy in patients with METAVIR fibrosis scores (MFS) of F2 or F3 who previously failed hepatitis C retreatment...
  27. ncbi Sampling variability of liver biopsy in nonalcoholic fatty liver disease
    Vlad Ratziu
    Service d Hepatogastroenterologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Gastroenterology 128:1898-906. 2005
    ..The aim of this study was to assess the sampling error of liver biopsy and its impact on the diagnosis and staging of NASH...
  28. ncbi Model for end-stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure
    Dominique Thabut
    AP HP Service d Hépato Gastroentérologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Hepatology 46:1872-82. 2007
    ..001). In multivariate analysis, only model for end-stage liver disease score and presence of SIRS, but not infection, remained associated with a poor outcome...
  29. ncbi FibroTest-FibroSURE: towards a universal biomarker of liver fibrosis?
    Thierry Poynard
    Groupe Hospitalier Pitie Salpetriere, 47 83 boulevard de l Hopital, 75651 Paris Cedex 13, France
    Expert Rev Mol Diagn 5:15-21. 2005
    ..The possible causes of false negatives and positives are also better identified. These tests, which are now available in 12 countries, can facilitate the screening and management of the most frequent liver diseases...
  30. ncbi Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1
    Yves Benhamou
    Groupe Hospitalier Pitie Salpetriere, Service de d Hépato Gastroentérologie, Paris, France
    J Hepatol 44:62-7. 2006
    ..Adefovir dipivoxil (10 mg once-daily) was added to antiretroviral therapy including lamivudine in 35 HIV/HBV co-infected patients...
  31. ncbi Treatment of hepatitis C virus: the first decade
    Thierry Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Semin Liver Dis 24:19-24. 2004
    ..Pegylated interferons used alone or in combination with ribavirin provide improved treatment options for different patient groups with chronic hepatitis C...
  32. doi Ranking hepatologists: which Hirsch's h-index to prevent the "e-crise de foi-e"?
    Thierry Poynard
    UPMC, Service d Hepato Gastroenterologie, Paris Liver Center, Groupe Hospitalier Pitie Salpetriere, AP HP, 47 83, Boulevard de l Hopital, 75651 Paris Cedex 13, France
    Clin Res Hepatol Gastroenterol 35:375-86. 2011
    ..The aim was to analyze the discordance rates in Hepatology between five h-I assessments from five databases: Scholar, Scopus, Web of Science (WoS), ScholarL restricted to "liver", and a specialty h-I HepaTop...
  33. doi Perspectives on fibrosis progression in hepatitis C: an à la carte approach to risk factors and staging of fibrosis
    Thierry Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitié Salpêtrière AP HP, University Paris 6, Paris, France
    Antivir Ther 15:281-91. 2010
    ..Incorporation of appropriately validated non-invasive assessments of liver fibrosis will likely improve the clinical care of patients with HCV infection...
  34. ncbi A comparison of fibrosis progression in chronic liver diseases
    Thierry Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, et UPRESA 8067 CNRS, 47 83 boulevard de l Hopital, 75651 Paris Cedex 13, France
    J Hepatol 38:257-65. 2003
    ..No study has compared the liver fibrosis progression rates among chronic liver diseases and the risk factors in order to better organize screening strategies...
  35. doi Assessment of adrenal function in cirrhotic patients: salivary cortisol should be preferred
    Arnaud Galbois
    Universite Pierre et Marie Curie, Service d Hepato Gastroenterologie, Hôpital de la Pitié Salpêtrière AP HP, Paris, France
    J Hepatol 52:839-45. 2010
    ....
  36. pmc Hirsch index and truth survival in clinical research
    Thierry Poynard
    University Pierre et Marie Curie Assistance Publique Hôpitaux de Paris Liver Center, Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
    PLoS ONE 5:e12044. 2010
    ..We hypothesized that publications with a first author having a higher Hirsch' index value (h-I), which quantifies and predicts an individual's scientific research output, should have a longer half-life...
  37. doi Biomarkers of liver injury for hepatitis clinical trials: a meta-analysis of longitudinal studies
    Thierry Poynard
    University Pierre and Marie Curie Liver Center, Paris, France
    Antivir Ther 15:617-31. 2010
    ..We aimed to review evidence-based published data of biomarkers that have been validated as non-invasive alternatives to biopsy as end points for HBV and HCV infection trials...
  38. pmc Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease
    Vlad Ratziu
    Hepato Gastroenterology, AP HP Groupe Hospitalier Pitié Salpétrière, Paris, France
    BMC Gastroenterol 6:6. 2006
    ..The aim of this study was to determine the diagnostic utility of non-invasive markers of fibrosis, validated in chronic viral hepatitis and alcoholic liver disease (FibroTest, FT), in patients with NAFLD...
  39. doi Can nonalcoholic steatohepatitis be diagnosed without liver biopsy?
    Vlad Ratziu
    Universite Pierre et Marie Curie, Assistance Publique Hopitaux de Paris, Hopital Pitie Salpetriere, INSERM UMRS_893, CdR Saint Antoine, Paris, France
    Biomark Med 3:353-61. 2009
    ..A noninvasive diagnosis of NASH would facilitate screening and monitoring of populations at risk, as well as the conduct of therapeutic trials...
  40. pmc Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest)
    Thierry Poynard
    APHP UPMC Liver Center, Assistance Publique Hopitaux de Paris, Universite Pierre et Marie Curie, Paris, France
    BMC Gastroenterol 10:40. 2010
    ..One challenge was to use them for estimating the prevalence of fibrosis, identifying independent risk factors and to propose screening strategies in the general population...
  41. ncbi Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages
    Thierry Poynard
    Assistance Publique Hôpitaux de Paris Groupe Hospitalier Pitié Salpêtrière, Paris, France
    Clin Chem 53:1615-22. 2007
    ..The aim of this study was to assess the relationships between the AUC and the prevalence of each fibrosis stage and to elaborate simple methods of standardization...
  42. ncbi [Can metabolic steatohepatitis be treated?]
    Vlad Ratziu
    Groupe Hospitalier Pitié Salpêtrière et Université Pierre et Marie Curie, Paris
    Gastroenterol Clin Biol 31:333-40. 2007
  43. ncbi Treatment of chronic hepatitis B virus infection in patients co-infected with human immunodeficiency virus
    Yves Benhamou
    Service d Héparo Gastroentérologie, Hopital Pitie Salpetriere, 27 boulevard de l Hopital, 75013 Paris, France
    J Hepatol 39:S194-9. 2003
  44. doi Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy
    Thierry Poynard
    Service d Hepatologie, Université Pierre et Marie Curie Liver Center, hôpital La Pitié Salpêtrière, Paris, France
    Gastroenterology 136:1618-28.e2. 2009
    ..Alternate options are needed for patients who relapse or do not respond to therapy...
  45. doi Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial
    Vlad Ratziu
    Universite Pierre et Marie Curie Paris VI, Assistance Publique Hopitaux de Paris, Service d Hepatogastroenterologie, Paris, France
    Gastroenterology 135:100-10. 2008
    ..Nonalcoholic steatohepatitis (NASH) is a liver disease that complicates insulin-resistant states. This trial tested the efficacy and safety of rosiglitazone, an insulin-sensitizing agent, in patients with NASH...
  46. ncbi Fibrogenic impact of high serum glucose in chronic hepatitis C
    Vlad Ratziu
    Service d Hepatogastroenterologie, Hopital Pitie Salpetriere, 47 83 Bd de l Hopital, Paris 75013, France
    J Hepatol 39:1049-55. 2003
    ..We tested the hypothesis that high serum glucose and overweight might contribute to this variability...
  47. ncbi Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis
    Vlad Ratziu
    Service d Hepatogastroenterologie, Hopital Pitie Salpetriere, Paris, France
    Hepatology 35:1485-93. 2002
    ..Increased awareness of and better diagnostic strategies for nonalcoholic steatohepatitis in overweight patients are urgently needed...
  48. ncbi Truth survival in clinical research: an evidence-based requiem?
    Thierry Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, 47 83 boulevard de l Hopital, 75651 Paris Cedex 13, France
    Ann Intern Med 136:888-95. 2002
    ..Factors associated with the survival of truth of clinical conclusions in the medical literature are unknown. The authors hypothesized that conclusions derived from studies using better methodology should have a longer half-life...
  49. ncbi Diagnosis and treatment of viral liver fibrosis
    Thierry Poynard
    Groupe Hospitalier Pitie Salpetriere, Paris, France
    Saudi J Gastroenterol 11:1-19. 2005
    ..In patients with chronic hepatitis Delta, pegylated interferon is also effective in reducing fibrosis progression...
  50. ncbi [Should we have the courage to say no to systematic liver biopsy?]
    Thierry Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, CNRS UPRESA 8067, 75651, Paris Cedex 13
    Gastroenterol Clin Biol 27:844-6; author reply 846. 2003
  51. pmc A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease
    Philippe Halfon
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, AP HP, Université Paris 6 et UPRESA 8067 CNRS Paris, 47 Boulevard de l Hopital, 75651 Paris Cedex 13, France
    Comp Hepatol 1:3. 2002
    ..Standardized methods and assay calibration should be used and expression of alanine aminotransferase and gamma-glutamyl transpeptidase in multiples of the upper limit of reference values should not be employed...
  52. ncbi Recombinant activated factor VII in chronic liver diseases: should we be afraid of thromboembolic events?
    Dominique Thabut
    Universite Pierre et Marie Curie, Service d Hepato Gastroenterologie, Hôpital de la Pitié Salpêtrière AP HP, Paris, France
    J Hepatol 55:483-5. 2011
  53. ncbi Portal lymphocytic infiltrate in alcoholic liver disease
    Magali Colombat
    Service Central d Anatomie Pathologique, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Hum Pathol 33:1170-4. 2002
    ..These results suggest that lymphocytes may play a role in the pathogenesis of alcohol-induced liver fibrosis...
  54. ncbi [What are the indications for treatment of acute hepatitis C?]
    Robert P Myers
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Paris
    Gastroenterol Clin Biol 26:B188-93. 2002
  55. doi Low 25-hydroxyvitamin D serum levels correlate with the presence of extra-hepatic manifestations in chronic hepatitis C virus infection
    Benjamin Terrier
    Department of Internal Medicine, Groupe Hospitalier Pitie Salpetriere, 47 Boulevard de l Hopital, 75013 Paris, France
    Rheumatology (Oxford) 51:2083-90. 2012
    ..Recent studies have suggested an immunomodulatory role for vitamin D during HCV infection. We investigated the association between serum vitamin D status and the presence of HCV extra-hepatic manifestations...
  56. ncbi Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study
    Samy Louafi
    Service d Hepato gastro enterologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Cancer 109:1384-90. 2007
    ..In a Phase II trial involving previously untreated patients with advanced HCC, the more favorable schedule from a previous pilot study was evaluated...
  57. ncbi Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules
    Julien Taieb
    Service d Hepato gastro enterologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Cancer 98:2664-70. 2003
    ..Therefore, the authors evaluated the activity and toxicity of two such combinations in patients with HCC...
  58. ncbi Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience
    Mona Munteanu
    Biopredictive, and Groupe Hospitalier Pitié Salpêtrière, 47 83 boulevard de l Hopital, Paris, France
    J Gastrointestin Liver Dis 17:187-91. 2008
  59. doi Noninvasive assessment of liver fibrosis in patients with Fontan circulation using transient elastography and biochemical fibrosis markers
    Mireen Friedrich-Rust
    Department of Internal Medicine, JW Goethe University Clinic, Frankfurt, Germany
    J Thorac Cardiovasc Surg 135:560-7. 2008
    ..Therefore, early detection of fibrosis is essential to identify patients at risk. Transient elastography has been evaluated for noninvasive staging of liver fibrosis in a multitude of studies...
  60. ncbi Viral hepatitis B
    Ching Lung Lai
    Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong, People s Republic of China
    Lancet 362:2089-94. 2003
    ..Lamivudine, and presumably other nucleoside analogues, can reverse cirrhosis of the liver...
  61. doi Screening for liver fibrosis by using a noninvasive biomarker in patients with diabetes
    Sophie Jacqueminet
    Service de Diabetologie, APHP GHPS, Paris, France
    Clin Gastroenterol Hepatol 6:828-31. 2008
    ..We examined the efficacy of a screening strategy with a noninvasive fibrosis biomarker (FibroTest) in patients with diabetes...
  62. ncbi [Hepatocellular carcinoma and non alcoholic steatohepatitis: are we looking at the tip of the iceberg?]
    Vlad Ratziu
    Service Hepatogastroenterologie, Hopital Pitie Salpetriere, Paris
    Gastroenterol Clin Biol 27:869-75. 2003
  63. ncbi Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients
    Robert P Myers
    Department of Hepatology and Gastroenterology, hôpital La Pitié Salpêtrière, Paris, France
    AIDS 17:721-5. 2003
    ..Our aim was to determine the operating characteristics of a non-invasive index of biochemical markers for the prediction of fibrosis in patients with HIV/HCV co-infection...
  64. ncbi Optimal correlation between different instruments for Fibrotest-Actitest protein measurement in patients with chronic hepatitis C
    Maria Alessandra Rosenthal-Allieri
    Laboratoire central d immunologie, CHU de Nice, Hopital de l Archet, Nice Université de Nice Sophia Antipolis, 151 route Saint Antoine de Ginistière, Nice
    Gastroenterol Clin Biol 31:815-21. 2007
    ..The aims of this study were to evaluate the analytical variability of the Fibrotest-Actitest proteins alpha 2-macroglobulin, haptoglobin and apolipoprotein-A1, and to assess their impact on the Fibrotest-Actitest scores...
  65. ncbi Long-term impact of renal transplantation on liver fibrosis during hepatitis C virus infection
    Laurent Alric
    Service de Medecine Interne, Pavillon Dieulafoy, CHU Purpan, Toulouse, France
    Gastroenterology 123:1494-9. 2002
    ....
  66. ncbi Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C
    John G McHutchison
    Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27715, USA
    Gastroenterology 123:1061-9. 2002
    ..We evaluated the impact of adherence to combination therapy with interferon or peginterferon plus ribavirin in chronic hepatitis C patients...
  67. ncbi Biochemical markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis C
    Robert P Myers
    Department of Hepato Gastroenterology, hôpital La Pitié Salpêtrière, Paris, France
    Am J Gastroenterol 97:2419-25. 2002
    ..The aims of this study were: 1) to compare an index of five biochemical markers with historical features; and 2) to determine the utility of combining these features with the five-marker index for the prediction of significant fibrosis...
  68. ncbi Diagnostic value of FibroTest with normal serum aminotransferases
    Thierry Poynard
    Hepatology 43:374-5; author reply 375-6. 2006
  69. ncbi Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C
    Thierry Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Universite Paris VI, Paris, France
    Gastroenterology 122:1303-13. 2002
    ..Liver fibrosis is an important prognostic factor in patients with hepatitis C. The effect of pegylated (PEG) interferon alone or its combination with ribavirin on fibrosis has not been established...
  70. ncbi Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin
    John G McHutchison
    Division of Gastroenterology Hepatology, Scripps Clinic and Research Foundation, 10666 N Torrey Pines Road N203, La Jolla, CA 92037, USA
    Hepatology 35:688-93. 2002
    ..In conclusion, measurement of hepatic HCV RNA before or after therapy reflects changes observed in serum HCV RNA, and correlates inversely with hepatic inflammation and fibrosis, but otherwise has minimal clinical use...
  71. ncbi The renal tolerance of low-dose adefovir dipivoxil by lamivudine-resistant individuals co-infected with hepatitis B and HIV
    Heidi Hannon
    Nephrology Department, Hôpital Pitié Salpétrière and CNRS UPRESA 8087, Paris, France
    Nephrol Dial Transplant 19:386-90. 2004
    ..Recently, lower doses of ADV were shown to be effective for the treatment of HIV-1 patients with chronic lamivudine (LAM)-resistant hepatitis B...
  72. ncbi [Non invasive markers using for the assessment of fibrosis in hepatitis C]
    Jean Pierre Zarski
    Clinique universitaire d hepato gastroentérologie, pôle DIGI DUNE, Unité INSERM U 548, CHU de Grenoble, Grenoble Cedex 9
    Gastroenterol Clin Biol 31:4S34-9. 2007
    ..Diagnostic accuracy is improved by the using of all the markers, especially of Fibrotest. Transient elastography is also a promising method for assessing the severity of cirrhosis...
  73. ncbi Intermethod calibration of alanine aminotransferase (ALT) and gamma-glutamyltransferase (GGT) results: application to Fibrotest and Actitest scores
    Georges Ferard
    Faculte de Pharmacie, Universite Louis Pasteur de Strasbourg, Illkirch, France
    Clin Chem Lab Med 44:400-6. 2006
    ..8% and 3.3% for ALT and GGT, respectively. For each enzyme, it also permitted the retention of a common reference interval for a set of calibrated methods and the improvement of inter-laboratory coherency of Fibrotest and Actitest scores...
  74. ncbi Non-invasive diagnosis of large oesophageal varices with FibroTest in patients with cirrhosis: a preliminary retrospective study
    Dominique Thabut
    Hepatogastroenterology Unit, Pitie Salpetriere Hospital, 47 bd de l Hopital, 75013 Paris, France
    Liver Int 26:271-8. 2006
    ..As portal hypertension is related to liver fibrosis, this study aimed to assess the predictive value of FibroTest, a non-invasive marker of liver fibrosis, for the diagnosis of LOV in cirrhotic patients...
  75. ncbi Longterm course of mixed cryoglobulinemia in patients infected with hepatitis C virus
    Damien Sene
    Department of Internal Medicine, hôpital La Pitié Salpêtrière, Paris, France
    J Rheumatol 31:2199-206. 2004
    ..To describe epidemiological, clinical, and immunological characteristics and the longterm course of persistent mixed cryoglobulinemia (MC) in patients infected with hepatitis C virus (HCV)...
  76. ncbi Long-term therapy with lamivudine in renal transplant recipients with chronic hepatitis B
    Dominique Thabut
    Hepato Gastroenterology Unit, Hopital Pitie Salpetriere, Paris, France
    Eur J Gastroenterol Hepatol 16:1367-73. 2004
    ..The clinical features, course and viral mutations associated with the emergence of viral resistance in this population have not been well studied...
  77. ncbi Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: a multicenter phase II study with dose adjustment according to baseline serum bilirubin level
    Valerie Boige
    Gastrointestinal Oncology Unit, Department of Medicine, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    Eur J Cancer 42:456-9. 2006
    ..51 and 3 ULN. However, the antitumour activity of single agent CPT-11 was not significant in advanced HCC...
  78. ncbi Age and gender will survive to competing risks as fibrosis factors
    Thierry Poynard
    Gastroenterology 128:519-20; author reply 520-1. 2005
  79. ncbi Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease
    Sylvie Naveau
    Department of Hepato Gastroenterology, Hopital Antoine Beclere, Clamart, France
    Clin Gastroenterol Hepatol 3:167-74. 2005
    ..The aim of this study was to determine the diagnostic use of noninvasive markers of fibrosis in patients with chronic alcoholic liver disease...
  80. ncbi Biomarkers as a first-line estimate of injury in chronic liver diseases: time for a moratorium on liver biopsy?
    Thierry Poynard
    Gastroenterology 128:1146-8; author reply 1148. 2005
  81. ncbi A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients
    Ting Tsung Chang
    National Cheng Kung University Medical College, Tainan, Taiwan
    Gastroenterology 129:1198-209. 2005
    ..This randomized, dose-ranging, phase 2 study compared the efficacy and safety of entecavir with lamivudine in lamivudine-refractory patients...
  82. ncbi Biological markers of liver fibrosis and activity as non-invasive alternatives to liver biopsy in patients with chronic hepatitis C and associated mixed cryoglobulinemia vasculitis
    Damien Sene
    Department of Internal Medicine, La Pitie Salpetriere Hospital, France
    Clin Biochem 39:715-21. 2006
    ..We assessed the reliability of non-invasive biological scoring indexes (Fibrotest-Actitest [FT-AT], Forns, APRI, age-platelet, platelet, hyaluronic acid) as non-invasive alternatives to liver biopsy (LB) in 138 HCV-infected patients...
  83. ncbi Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease?
    Dominique Thabut
    Services d Hépato gastroentérologie, Group Hospitalier Pitié Salpêtrièe, Paris, France
    Am J Gastroenterol 101:1260-7. 2006
    ....
  84. ncbi In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir
    Olivier Lada
    Virology, AP HP Pitié Salpêtrière Hospital, Paris, France
    Antivir Ther 9:353-63. 2004
    ..The excellent activity of TDF on lamivudine-resistant virus independently of the resistance mutation profile offers an interesting treatment alternative to HIV-HBV coinfected patients...
  85. ncbi The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C
    Sophie Le Calvez
    Hepatology 39:862-3; author reply 863. 2004
  86. ncbi Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors
    Francoise Imbert-Bismut
    Service of Biochemistry, hôpital La Pitié Salpêtrière, Paris, France
    Clin Chem Lab Med 42:323-33. 2004
    ..075+/-0.004 and 0.068+/-0.004, respectively. The low intra-laboratory and intra-patient variability in Fibrotest and Actitest results confirm Fibrotest and Actitest reliability...
  87. ncbi Decreased frequencies of virus-specific T helper type 1 cells during interferon alpha plus ribavirin treatment in HIV-hepatitis C virus co-infection
    Nadia Alatrakchi
    Laboratoire d Immunologie Cellulaire et Tissulaire INSERM U543, Centre Hospitalier Universitaire Pitie Salpetriere, Paris, France
    AIDS 18:121-3. 2004
    ..This suggests that IFN+R therapy might compromise virus-specific immune defenses in immunosuppressed patients...
  88. pmc Association between leptin, metabolic factors and liver histology in patients with chronic hepatitis C
    Robert P Myers
    Department of Medicine, University of Calgary, Calgary, Canada
    Can J Gastroenterol 21:289-94. 2007
    ..The objective of the present study was to determine the clinical and histological correlates of serum leptin in HCV-infected patients, and to determine its utility in predicting liver histological lesions...
  89. ncbi Risk factors for liver fibrosis progression in patients with chronic hepatitis C
    Mercedes De Torres
    Service d Hépato Gastroentérologie Groupe, Hospitalier Pitié Salpêtrière, 47 83 boulevard de l Hopital, 75651 Paris Cedex 13, France
    Ann Hepatol 2:5-11. 2003
    ....
  90. ncbi Prevalence of irritable bowel syndrome (IBS) and variability of diagnostic criteria
    Gilles Bommelaer
    Service d Hepato Gastroenterologie, hôpital de l Hôtel dieu, Clermont Ferrand
    Gastroenterol Clin Biol 28:554-61. 2004
    ....
  91. ncbi Effect of prolonged interferon therapy on the outcome of hepatitis C virus-related cirrhosis: a randomized trial
    Laetitia Fartoux
    AP HP, Hopital Saint Antoine, Paris, France
    Clin Gastroenterol Hepatol 5:502-7. 2007
    ..We designed a randomized controlled trial comparing the efficacy of prolonged IFN alfa-2a treatment vs nontreatment on complication-free survival in patients with compensated HCV cirrhosis...
  92. pmc Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease
    Thierry Poynard
    Hepato Gastroenterology, AP HP Groupe Hospitalier Pitié Salpétrière, Paris, France
    BMC Gastroenterol 6:34. 2006
    ..The aim was to develop and validate a new biomarker of non alcoholic steato hepatitis (NASH) the NashTest (NT) in patients with NAFLD...
  93. ncbi Fibrosis as an end point for clinical trials in liver disease: a report of the international fibrosis group
    John McHutchison
    GI Hepatology Research, Duke Clinical Research Institute, Durham, North Carolina 27707, USA
    Clin Gastroenterol Hepatol 4:1214-1220. 2006
    ..In this article, we summarize those discussions and attempt to highlight many of the hurdles and unanswered questions as we attempt to move forward and develop therapies to combat liver fibrosis...
  94. ncbi A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B
    Ching Lung Lai
    University of Hong Kong, China
    Gastroenterology 129:528-36. 2005
    ..A previous 4-week trial of telbivudine in patients with chronic hepatitis B indicated marked antiviral effects with good tolerability, leading to the present 1-year phase 2b trial...